You are here

  • Home
  • Archive
  • Volume 8, Issue 2
  • Safety of immune checkpoint inhibitor rechallenge after discontinuation for grade ≥2 immune-related adverse events in patients with cancer

Article metrics

Article menu
XML
Oncolytic and local immunotherapy
Original research
Safety of immune checkpoint inhibitor rechallenge after discontinuation for grade ≥2 immune-related adverse events in patients with cancer

 

Online download statistics by month:

Online download statistics by month: December 2020 to March 2023

AbstractFullPdf
Dec 202030830891
Jan 2021295295189
Feb 202117317399
Mar 202118118182
Apr 202111011073
May 202112212252
Jun 202113213269
Jul 2021757555
Aug 2021888849
Sep 2021737335
Oct 202113913998
Nov 202111811898
Dec 202113513564
Jan 2022878860
Feb 2022636849
Mar 202212212372
Apr 202212913053
May 202213613982
Jun 202212412789
Jul 202211411781
Aug 20229910283
Sep 202210110564
Oct 2022114118106
Nov 2022707039
Dec 202213713961
Jan 202315015070
Feb 202311611657
Total351135412020